[Congressional Record Volume 167, Number 145 (Tuesday, August 10, 2021)]
[Senate]
[Page S6326]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 3214. Mr. TUBERVILLE submitted an amendment intended to be 
proposed by him to the concurrent resolution S. Con. Res. 14, setting 
forth the congressional budget for the United States Government for 
fiscal year 2022 and setting forth the appropriate budgetary levels for 
fiscal years 2023 through 2031; which was ordered to lie on the table; 
as follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO A TAX 
                   CREDIT FOR THE DOMESTIC MANUFACTURE AND SALE OF 
                   PHARMACEUTICALS.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     Federal income taxes, which may include establishing a tax 
     credit of 20 percent of the net income earned from the 
     domestic manufacturing and sales of active pharmaceutical 
     ingredients and medical countermeasures produced in the 
     United States, by the amounts provided in such legislation 
     for those purposes, provided that such legislation would not 
     increase the deficit over either the period of the total of 
     fiscal years 2022 through 2026 or the period of the total of 
     fiscal years 2022 through 2031.
                                 ______